HKSE:06600 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:06600 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
SciClone Pharmaceuticals (Holdings)'s operating cash flow per share for the six months ended in Dec. 2023 was HK$1.40. SciClone Pharmaceuticals (Holdings)'s operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.37.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of SciClone Pharmaceuticals (Holdings) was 26.50% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 11.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 36.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for SciClone Pharmaceuticals (Holdings)'s Operating Cash Flow per Share or its related term are showing as below:
During the past 7 years, SciClone Pharmaceuticals (Holdings)'s highest 3-Year average Operating Cash Flow per Share Growth Rate was 86.20% per year. The lowest was 3.30% per year. And the median was 48.30% per year.
The historical data trend for SciClone Pharmaceuticals (Holdings)'s Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciClone Pharmaceuticals (Holdings) Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Operating Cash Flow per Share | Get a 7-Day Free Trial | 1.69 | 1.72 | 1.81 | 1.87 | 2.36 |
SciClone Pharmaceuticals (Holdings) Semi-Annual Data | |||||||||||
Dec17 | Dec18 | Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | |
Operating Cash Flow per Share | Get a 7-Day Free Trial | 1.24 | 0.87 | 1.04 | 0.97 | 1.40 |
For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
SciClone Pharmaceuticals (Holdings)'s Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share (A: Dec. 2023 ) | = | Cash Flow from Operations (A: Dec. 2023 ) | / | Shares Outstanding (Diluted Average) (A: Dec. 2023 ) |
= | 1535.971 | / | 650.433 | |
= | 2.36 |
SciClone Pharmaceuticals (Holdings)'s Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share (Q: Dec. 2023 ) | = | Cash Flow from Operations (Q: Dec. 2023 ) | / | Shares Outstanding (Diluted Average) (Q: Dec. 2023 ) |
= | 901.926 | / | 643.744 | |
= | 1.40 |
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Ubs Group Ag | 2201 Interest of corporation controlled by you | |
Zhao Hong | 2101 Beneficial owner | |
Gl Capital Management Gp Limited | ||
Meng Liang | 2201 Interest of corporation controlled by you | |
Ascendent Silver (cayman) Limited | 2501 Other | |
Ascendent Capital Partners Ii Gp Limited | 2201 Interest of corporation controlled by you | |
Ascendent Capital Partners Ii, Gp, L.p. | 2201 Interest of corporation controlled by you | |
Ascendent Capital Partners Ii, L.p. | 2201 Interest of corporation controlled by you | |
Gl Partners Capital Management Ltd. | ||
Gl China Opportunities Carry Gp Limited | ||
Ocean Falcon Limited | 2101 Beneficial owner | |
Central Huijin Investment Ltd. | 2201 Interest of corporation controlled by you | |
Bank Of China Limited | 2201 Interest of corporation controlled by you | |
Bank Of China Group Investment Limited | 2201 Interest of corporation controlled by you | |
Gl Capital Management Gp Ii B.c I. Ltd |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.